Inflammatory Bowel Diseases (IBD) Market

Table of Content

1. INTRODUCTION
   1. Study Assumptions and Market Definition
   2. Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
   1. Market Overview
   2. Market Drivers
      1. High prevalence rate of Crohn's disease and Ulcerative Colitis
   3. Market Restraints
      1. High Treatment Costs
      2. Adverse Effects of Immunomodulatory Therapies
   4. Market Opportunities
      1. Increase in the number of clinical trials
   5. Market Trends
      1. Personalized Medicine Approaches
      2. Adoption of Telemedicine and Digital Health Solutions
5. MARKET SEGMENTATION
   1. By Type
      1. Microscopic Colitis
      2. Ulcerative Colitis
      3. Crohn's Disease
   2. By Treatment
      1. Medication
      2. Corticosteroids
      3. Biologics
      4. Immunosuppressant
      5. Anti-diarrheal Medications
      6. Nonsteroidal anti-inflammatory drugs (NSAIDs)
      7. Antibiotics
      8. Others
      9. Surgery
      10. Others
   3. By Diagnosis
      1. Imaging Procedures
      2. Magnetic resonance imaging (MRI)
      3. Computerized tomography (CT) scan
      4. X-ray
      5. Endoscopic Procedures
      6. Balloon-assisted enteroscopy
      7. Capsule endoscopy
      8. Upper endoscopy
      9. Flexible sigmoidoscopy
      10. Colonoscopy
      11. Lab Tests
      12. Stool studies
      13. Tests for anemia or infection
   4. By Dosage Form
      1. Tablet
      2. Capsule
      3. Injections
      4. Others
   5. By Route of Administration
      1. Oral
      2. Parenteral
      3. Others
   6. By End-Users
      1. Hospitals
      2. Specialty Clinics
      3. Homecare
      4. Others
   7. By Distribution Channel
      1. Hospital Pharmacy
      2. Retail Pharmacy
      3. Online Pharmacy
      4. Others
   8. By Key Geographic Regions
      1. North America
         1. United States
         2. Canada
         3. Mexico
      2. Europe
         1. Germany
         2. United Kingdom
         3. France
         4. Italy
         5. Spain
         6. Rest of Europe
      3. Asia Pacific
         1. China
         2. Japan
         3. India
         4. Australia
         5. South Korea
         6. Rest of Asia Pacific
      4. Middle East and Africa
         1. GCC
         2. South Africa
         3. Rest of Middle East and Africa
      5. South America
         1. Brazil
         2. Argentina
         3. Rest of South America
6. COMPETITIVE LANDSCAPE
   1. Company Profile
      1. Allergan (Ireland)
      2. Aurobindo Pharma (India)
      3. AbbVie Inc. (U.S.)
      4. AstraZeneca (U.K.)
      5. Abbott (U.S.)
      6. Baxter (U.S.)
      7. Bayer AG (Germany)
      8. Bausch Health Companies Inc. (Canada)
      9. Eli Lilly and Company (U.S.)
      10. F. Hoffmann-La Roche Ltd. (Switzerland)
      11. GlaxoSmithKline plc (U.K.)
      12. Johnson & Johnson Private Limited (U.S.)
      13. Lupin (India)
      14. Merck & Co., Inc. (U.S.)
      15. Mylan N.V. (U.S.)
      16. Novartis AG (Switzerland)
      17. Pfizer Inc. (U.S.)
      18. Sanofi (France)
      19. Sun Pharmaceutical Industries Ltd. (India)
      20. Teva Pharmaceutical Industries Ltd. (Israel)
   2. MARKET OPPORTUNITIES AND FUTURE TRENDS

Frequently Asked Questions

Q.1. What is the projected market value of the global Inflammatory Bowel Diseases (IBD)market?

The global market of Inflammatory Bowel Diseases (IBD) is projected to reach USD 37.58 Bn by 2033.

Q.2. What is the estimated growth rate (CAGR) of the global Inflammatory Bowel Diseases (IBD)market?

The global Inflammatory Bowel Diseases (IBD) market has an estimated annual growth rate of 5.3%. 

Q.3. What are the recent trends of Inflammatory Bowel Diseases (IBD)market?

Personalized medicine approaches and adoption of telemedicine and digital health solutions are some of the major trends of the market that is projected to boost the market growth in the near future.

Q.4. Which are the top companies to hold the market share in Inflammatory Bowel Diseases (IBD)?

The major companies profiled in this report include Allergan (Ireland), Aurobindo Pharma (India), AbbVie Inc. (U.S.), AstraZeneca (U.K.), Abbott (U.S.), Baxter (U.S.), Bayer AG (Germany), Bausch Health Companies Inc. (Canada), Eli Lilly and Company (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), GlaxoSmithKline plc (U.K.), Johnson & Johnson Private Limited (U.S.), Lupin (India), Merck & Co., Inc. (U.S.), Mylan N.V. (U.S.), Novartis AG (Switzerland), Pfizer Inc. (U.S.), Sanofi (France), Sun Pharmaceutical Industries Ltd. (India), Teva Pharmaceutical Industries Ltd. (Israel), among others. 

Q.5. Which region is estimated to held highest CAGR inInflammatory Bowel Diseases (IBD)market?

North America is estimated to hold biggest share in the market for Inflammatory Bowel Diseases (IBD).